Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 12, 2026

Andy Jassy has great news for Amazon stock investors

View original at finance.yahoo.com
Andy Jassy has great news for Amazon stock investors For years, Amazon has asked Wall Street to be patient. The spending is heavy, the timeline is long, and the payoff is coming…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If Amazon sold its chips externally like Nvidia does, the business would be running at roughly $50 billion in annual revenue

    60% confidence

  • AWS AI revenue run rate is above $15 billion as of Q1 2026

    60% confidence

  • Trainium2 has largely sold out

    60% confidence

  • The chip business changes the economics for AWS and will be much larger than most think

    60% confidence

  • Our chips business is on fire

    60% confidence

  • AWS expects to double its total power capacity by the end of 2027

    60% confidence

  • Trainium4 has already been significantly reserved, about 18 months from broad availability

    60% confidence

  • Trainium3 is nearly fully subscribed

    60% confidence

  • Two large customers asked to buy all of Amazon's available Graviton chip capacity for 2026

    60% confidence

  • AI revenue numbers are ascending rapidly

    60% confidence

  • Amazon's chip business now has annual revenue run rate above $20 billion, growing at triple-digit rates year-over-year

    60% confidence

  • Some AWS customers are still unable to get the compute they want despite capacity additions

    60% confidence

Data points we hold from this source

Amazon Web Services · ai revenue run rate15 USD
Amazon Web Services · power capacity added3.9 gigawatts
Amazon Web Services · total revenue run rate142 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Andy Jassy has great news for Amazon stock investors — Source | Via News | ViaNews EU